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SUMMARY – The heterogeneity of rheumatoid arthritis (RA) presentation and molecular signa-
ture of RA subclasses in patients with early changes of small peripheral joints still remains a challen-
ging problem. In clinical setting, classification of the disease subtypes is not possible and treatment 
adjustment is based on the continuous Disease Activity Score for disease severity recognition. A new 
approach in the treatment appears with the novel non biologic targeted synthetic disease-modifying 
antirheumatic drugs from the group of Janus kinase 1 and 3 (JAK1 and JAK3), blocking interleukin 
(IL)-2, IL-4, IL-7, IL-9, IL-15 and IL-21. We report a case of a 48-year-old patient who had suffered 
from polyarthritis from his age 40. Initial laboratory tests showed low inflammatory parameters and 
magnetic resonance imaging of both hands indicated an early stage of RA. Methylprednisolone and 
methotrexate therapy was initiated. The patient underwent additional tests, but there was not sufficient 
evidence for a precise diagnosis. According to the European League Against Rheumatism/American 
College of Rheumatology score-based algorithm, the patient was classified as seronegative RA based 
on joint involvement, duration of the disease, and synovitis not better explained by another disease. A 
partial clinical effect of the administered therapy (steroids as monotherapy and in combination, met-
hotrexate and leflunomide) was noticed with the use of systemic steroids, but dramatic improvement 
was only achieved with a JAK inhibitor targeted therapy. Although the use of anti TNF-α blocker is 
a proposed procedure and the drug has not yet been registered in Europe, we took the opportunity 
to apply this new medication option. The patient, a construction worker, was treated for 20 months, 
which led to complete remission of the disease, without the need of basic or corticosteroid therapy. Full 
functional capacity necessary in his demanding job was also achieved. This result raised a question of 
timely introduction of immunomodulators in the polyarthritis treatment steps. 
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Introduction
Early changes of small peripheral joints can be a 
great diagnostic puzzle even for an experienced rheu-
matologist. Clinical findings of painful, swollen and 
functionally damaged small joints are commonly seen 
in inflammatory conditions with different etiopatho-
genesis, such as rheumatic arthritis (RA), reactive 
arthritis and psoriatic arthritis. Differential diagnosis 
also includes gout1-5, the most common type of in-
flammatory arthritis6. Precise diagnosis is particularly 
difficult to make in the initial phase of disease, posing 
difficulties on making treatment decision. 
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A network of intercellular signaling cytokines is 
the central control mechanism in the pathogenesis 
of RA. Cytokine patterns vary over time: early RA 
involves interleukin (IL)-4, IL-13 and IL-15, while 
in chronic disease the central role of tumor necrosis 
factor (TNF)-α and IL-6 has been confirmed by 
successful therapeutic blockade in clinical setting7. 
Besides intercellular, there are many intracellular sig-
naling molecules (particularly kinases) that regulate 
the cytokine-receptor-mediated functions. Janus ki-
nase 1 (JAK1) mediates the function of several cy-
tokines, interferons and growth factors, which has 
been confirmed by positive clinical outcomes of JAK1 
blockade8,9.
The heterogeneity of RA patient presentation and 
molecular signature of RA subclasses still remains 
a challenging problem. By genome-wide expression 
profiling technologies of disease-relevant gene co-
clusters and correlation analysis with clinical param-
eters, researchers are trying to provide evidence for 
the molecular signature of the disease10,11.
Predictive power to identify seronegative (anti-
citrullinated peptide antibody) patients with early ar-
thritis at risk of developing RA belongs to the CD4 T 
cell gene signature, which implicates IL-6-mediated 
STAT3 signaling12. Upregulation of SPP1-like clus-
ter genes can serve to distinguish rheumatoid arthritis 
and other entities (i.e. osteoarthritis). A higher level of 
SPP1 protein can be detected in synovial fluids from 
RA patients. SPP1 is a secreted phosphoglycoprotein 
functioning as a cytokine, DC activator and co-stim-
ulator of T cell proliferation.
In clinical setting, classification of the disease sub-
types is not possible. Treatment adjustment is based 
on continuous Disease Activity Score (DAS) mea-
surements for disease severity recognition (‘treat-to-
target’ concept)13-17. 
A new approach in the treatment of RA patients 
has appeared with the development of new non bio-
logic targeted synthetic disease-modifying antirheu-
matic drugs (tsDMARDs) from the group of JAK in-
hibitors. JAK exhibits the function of some cytokines, 
interferon and growth hormone18. The inhibition of 
Janus kinase 1 and 3 (JAK1 and JAK3) blocks IL-2, 
IL-4, IL-7, IL-9, IL-15 and IL-21 and modulates the 
immune response.
The aim of this case report is to remind that clas-
sification of the disease subtype and effective RA 
treatment are impeded by the paucity of accurate di-
agnostic tests. Also, excellent clinical response to JAK 
inhibitor was demonstrated in a clinical trial, in a pa-
tient who, due to technical reasons, could not have 
previously received TNF-α blockers.
Case Report
A 48-year-old patient had suffered from polyar-
thritis for eight years. The patient noticed the symp-
toms two years before seeking medical care. No simi-
lar symptoms were reported in the family medical 
history. Swelling, redness, pain and functional distur-
bances appeared in the frontal part of his feet, knees, 
carpometacarpal and metacarpophalangeal joints, bi-
laterally. The initial blood test results were within the 
reference ranges (complete blood count, erythrocyte 
sedimentation rate, transaminases, creatinine and 
urea), with the only exception of slightly increased 
uric acid, measuring 404 µmol/L (reference range: 
182-403 µmol/L). Oral therapy with methylpredni-
solone (daily dose of 20 mg) along with nonsteroidal 
anti-inflammatory drugs was introduced. Consider-
ing the normal values of rheumatoid factor (RF) and 
C-reactive protein (CRP), as well as the wrist x-ray 
showing no pathological changes, the early stage of 
RA was diagnosed and methotrexate was added in 
therapy in a weekly dose of 7.5 mg. However, diag-
nostic procedures failed to indicate a definitive diag-
nosis and therapy did not result in disease remission. 
The prescribed therapy was continued and the patient 
was treated for the next two years. 
Over the two-year period, Ureaplasma urealyticum 
was isolated from the urethral smear and antibiotics 
were administered without any effect on the disease 
progression. HLA typing determined the A 2.11, B 
13.35, DR 1.7.53, DQ 1.2 loci.
On additional diagnostic workup, magnetic res-
onance imaging (MRI) of both hands (Figs. 1-3) 
showed signs of tenosynovitis of flexor tendons, 
bone marrow edema, tethering of tissue with erosion 
of the joint surface, which was interpreted as RA. 
A daily dose of 20 mg of leflunomide and a weekly 
dose of 12.5 mg of methotrexate was introduced in 
therapy. After a liver lesion developed, as indicated 
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by the high liver enzymes alanine transaminase 120 
U/L (reference range: 12-48 U/L), aspartate amin-
otransferase 59 U/L (reference range: 1-38 U/L) and 
γ-glutamyltransferase 74 U/L (reference range: 1-55 
U/L), methotrexate therapy was substituted by meth-
ylprednisolone (daily dose of 10 mg). Due to the side 
effects of methylprednisolone, the patient reduced the 
dosage on his own. With dosage reduction below 5 
mg a day, relapse of the disease occurred. Screening 
for other autoimmune diseases was negative.
More than 5 years of the presence of clinical symp-
toms despite DMARD and corticosteroid therapy, 
oral therapy with JAK inhibitor was introduced in a 
daily dose of 2x10 mg, together with the existing dose 
of methylprednisolone of 10 mg daily. The outcome 
of this therapy was reduction of all symptoms and re-
gression of swelling, which occurred after one month, 
and total remission of the disease without the need 
of further symptomatic therapy, which was achieved 
after 20 months of therapy with JAK inhibitor in the 
same dosage. To the present, the patient has been tak-
ing JAK inhibitor monotherapy, without any subjec-
tive problems. 
Discussion
There is wide variation in the responsiveness to 
virtually any treatment in RA consistent with the 
heterogeneous nature of the disease. For better de-
tection of diverse cellular responses in general, and 
for classification of the disease subtypes which could 
enable more specific medication choices, a molecular 
portrait in the diagnostic procedure is necessary19. In 
daily clinical practice, DAS represents actual disease 
Fig. 3. Magnetic resonance imaging: coronal Short TI In-
version Recovery (STIR) sequence of both hands.
Fig. 1. Magnetic resonance imaging: T1 weighted coronal 
image of both hands.
Fig. 2. Magnetic resonance imaging: T1 
weighted transverse image of the left hand.
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activity well in the majority of patients. Clinical tri-
als as well as clinical practice have demonstrated this 
concept to be effective in achieving remission in early 
RA20,21. However, precise defining of the entity and 
the right choice of therapy can pose a problem, espe-
cially in initial stages of the disease. 
In the patient presented, the initial test results 
were not informative enough to differentiate rheuma-
tologic entities and to make a precise diagnosis. There 
was no complete evidence for diagnosing RA (nega-
tive RF and anti cyclic citrullinated peptide (aCCP), 
low parameters of system inflammation)22.
According to the European League Against 
Rheumatism/American College of Rheumatology 
(EULAR-ACR) score-based algorithm, the patient 
was classified as seronegative RA based on joint in-
volvement, duration of the disease and synovitis not 
better explained by another disease. Current classifi-
cation simplifies categorization of patients with early 
RA; however, the diagnosis requires a highly trained 
specialist able to differentiate early symptoms of RA 
from other pathology. In some patients, it requires at 
least five years or more from the onset of symptoms to 
the diagnosis to meet the minimum diagnosis system 
requirements.
In the presented patient, elements of psoriatic 
arthritis, in differential diagnostic procedures, were 
not established either by physical examination or by 
positive medical history or typical HLA genotype23,24. 
Moreover, the role of higher values of uric acid as the 
etiology of arthritis did not appear to be meaningful. 
The omission of HLA-B 27, despite positive testing 
for Ureaplasma urealyticum, brings the diagnosis of se-
ronegative spondyloarthropathies into question25,26.
According to literature data27-29, the greatest diag-
nostic help in such cases is MRI, which shows joint 
structure and soft tissue in detail30. Typical MRI 
shows thickening of synovial membrane, pannus for-
mation, tendinitis, bone marrow edema, and bone ero-
sion. In the present case report, bone marrow edema 
pointed to RA, but as similar test results can also be 
found in the group of patients with psoriatic arthritis 
(symmetrical inflammation of joints inside the syn-
ovial cavity), it is not always possible to differentiate 
it from RA31.
In our patient, the disease relapse was not always 
accompanied with the signs of systemic inflammation, 
which did not fit in the typical RA patient profile and 
did not help judge the level of arthritis suppression. 
A partial clinical effect of the administered therapy 
(steroids as monotherapy and in combination, metho-
trexate and leflunomide) was noticed with the use of 
systemic steroids, but dramatic improvement was only 
achieved with the JAK inhibitor targeted therapy. 
Significantly, JAK inhibitor plays its role in blocking 
cytokine receptors with common gamma chain, fur-
ther signal transduction and gene transcription32-34. It 
is blocking IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21, 
the cytokines secreted in various immune conditions, 
as demonstrated not only in rheumatic diseases but 
also in psoriasis, keratoconjunctivitis, inflammatory 
intestinal diseases, prevention of transplant rejection, 
and cancer35-44.
Exclusive cytokine expression patterns are charac-
teristic of a distinct autoimmune disease. For example, 
in a subgroup of patients with RA, IFN type I molec-
ular signature is upregulated, but it could mean that 
this cytokine profile is patient-specific rather than a 
disease-specific phenomenon. A further characteris-
tic of this subgroup of patients is increased activity of 
complement and coagulation cascades. IFN/STAT-1 
activation in RA synovium could be an attempt to 
limit inflammation45. However, there is evidence for 
cytokine hierarchy in RA with TNF-α at its peak46. 
But, blockade of TNF and IL-6 have a similar in-
hibitory effect on joint damage progression in patients 
with either early or late disease47. Compared with cy-
tokine inhibition, B-cell depletion and inhibition of 
T cell co-stimulation have a somewhat delayed effect 
on joint damage, suggesting their effect on upstream 
pathogenetic events. 
Our patient, a construction worker, was treated 
with JAK inhibitor for 20 months, which led to com-
plete remission of the disease, without the need of 
basic or corticosteroid therapy, as well as to full func-
tional capacity in his demanding job.
Conclusion
This case report of a patient with chronic small 
peripheral joint arthritis and without evidence of tol-
erance against citrullinated antigens breaking demon-
strates that distinct disease mechanisms are at play in 
RA pathology. We aimed to emphasize that effective 
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RA treatment is currently impeded by the paucity of 
accurate diagnostic and prognostic tests in the early 
disease. The main question in our patient treatment 
was how the then-available medication could best be 
used. Although the use of anti TNF-α blocker is the 
proposed procedure and the drug has not yet been 
registered in Europe, we used the opportunity to ap-
ply the JAK inhibitor. The result showed total sup-
pression of rheumatoid activity and raised a question 
of timely use of immunomodulators in polyarthritis 
treatment steps.
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Sažetak
KLINIČKI ODGOVOR NA JAK INHIBITORE U BOLESNIKA S POLIARTRITISOM: PRIKAZ SLUČAJA
A. Stipić-Marković, I. Ferček, M. Čubela, M. Artuković, K. Maštrović Radončić i L. Lugović-Mihić
Raznolikost kliničke slike reumatoidnog artritisa (RA) i molekularna specifičnost podvrsta RA kod bolesnika s ranim 
promjenama na perifernim zglobovima još uvijek predstavljaju velik izazov. U kliničkim uvjetima klasifikacija podtipova 
bolesti nije moguća, a prilagodba terapije temelji se na kontinuiranoj ljestvici DAS za procjenu težine bolesti. Novi pristup 
u liječenju pojavljuje se s novim ne-biološkim ciljnim sintetskim antireumaticima koji modifciraju bolest (targeted synthetic 
disease-modifying antirheumatic drugs, tsDMARDs) iz skupine Janus kinaza 1 i 3 (JAK1 i JAK3) koji blokiraju interleukin 
(IL)-2, IL-4, IL-7, IL-9, IL- 15 i IL-21. Prikazuje se slučaj 48-godišnjeg bolesnika koji je u dobi od 40 godina obolio od 
poliartritisa. Početni laboratorijski nalazi pokazali su mirne upalne parametre, a nalaz magnetske rezonancije obiju šaka 
ukazivao je na rani stadij RA. U terapiju su uvedeni metilprednizolon i metotreksat. Bolesnik je prošao dodatnu obradu, 
ali nije bilo dovoljno elemenata za postavljanje točne dijagnoze. Prema algoritmu EULAR-ACR bolest je klasificirana kao 
seronegativni RA s obzirom na zahvaćenost zglobova, trajanje bolesti i sinovitis koji se nisu mogli bolje opisati kao neki 
drugi entitet. Djelomičan klinički odgovor na danu terapiju (steroidi u monoterapiji te metotreksat i leflunomid u kombi-
naciji) zabilježen je pri upotrebi sistemskih steroida, no dramatično poboljšanje postignuto je tek upotrebom ciljane terapije 
JAK inhibitorima. Iako je po preporukama indicirana upotreba anti TNF-α blokatora, iskoristili smo priliku primijeniti 
novi lijek iako isti još nije registriran u Europi. Nakon dvadeset mjeseci liječenja JAK inhibitorom kod ovog bolesnika, 
građevinskog radnika, došlo je do potpune remisije bolesti bez potrebe za bazičnom ili kortikosteroidnom terapijom. 
Također je postignut i potpuni funkcionalni kapacitet u njegovom zahtjevnom zanimanju. Dobiveni rezultati dovode u 
pitanje pravodobnost davanja imunomodulatora u algoritmu liječenja poliartritisa.
Ključne riječi: Reumatoidni artritis – terapija; Janusove kinaze – antagonisti i inhibitori; Adjuvansi, imunološki
